Chronic Myelogenous Leukemia

CML is defined by the Philadelphia chromosome, created by t(9;22), which produces a BCR::ABL1 fusion gene. Most patients in developed settings present in chronic phase, but phase assignment at diagnosis is essential because therapeutic goals and urgency differ substantially in accelerated- and blast-phase disease. PubMedPubMedChronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology - PubMed

Obtain complete blood count with differential, chemistry testing, physical examination including spleen assessment, bone marrow aspirate for morphology and conventional cytogenetics, and BCR::ABL1 testing. Baseline qualitative RT-PCR identifies the transcript type; quantitative RT-PCR provides the baseline molecular burden for later monitoring. Core biopsy is useful when aspiration is inadequate or marrow architecture requires assessment. PubMedPubMedChronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review

Fluorescence in situ hybridization is principally useful when conventional cytogenetics does not demonstrate a Philadelphia chromosome but CML remains suspected. Baseline marrow cytogenetics also identifies additional chromosomal abnormalities that may affect disease assessment and subsequent interpretation of treatment response. PubMedPubMedChronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review

TKIs have transformed chronic-phase CML management and are highly effective at preventing progression to advanced disease. Current management increasingly balances durable disease control with tolerance, comorbidity burden, quality of life, and whether a patient may ultimately pursue treatment-free remission. Nature+1Nature2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia | LeukemiaPubMedChronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology - PubMed

Frontline chronic-phase treatment is based on TKI therapy in virtually all patients. Choice among agents should account for expected efficacy, prior cardiovascular and pulmonary history, metabolic risks, concomitant medications, toxicity tolerance, and patient preference; the available search evidence does not provide sufficient support for agent-specific U.S. dosing or a complete selection algorithm. Wiley+1WileyDeterminants of frontline tyrosine kinase inhibitor choice for ...PubMedChronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology - PubMed

Asciminib is a STAMP inhibitor that binds the ABL1 myristoyl pocket rather than the ATP-binding site targeted by conventional TKIs. It is described as an option for chronic-phase CML after resistance or intolerance to at least two TKIs, including T315I-positive disease; confirm current U.S. labeling, indication, and dose before prescribing because the supplied evidence is not an FDA label. Wolters KluwerWolters KluwerA new chapter in CML treatment: the promise of... : Annals of Medicine & Surgery

Quantitative BCR::ABL1 measurement by PCR standardized to the International Scale is an essential component of CML management. Serial molecular testing provides a precise, minimally invasive measure of response and should be interpreted longitudinally in the context of baseline transcript type, treatment exposure, adherence, and assay performance. PubMedPubMedChronic Myelogenous Leukemia, Version 1.2014

A BCR::ABL1 level of 10% or less on the International Scale is a cited early response milestone at 3 and 6 months. Historical NCCN guidance recommended continued same-dose TKI therapy with testing every 3 months for patients at or below this level, while levels above 10% triggered reassessment, including adherence and drug-interaction review, and consideration of another TKI or a clinical trial. Current decisions should be reconciled with the latest NCCN guidance. PubMedPubMedChronic Myelogenous Leukemia, Version 1.2014

Failure and warning are distinct ELN response categories. Failure generally requires a therapy change after nonadherence is considered; warning permits either continuation or change after integrating molecular-response kinetics, comorbidities, tolerance, and patient characteristics. NatureNatureEuropean LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia | Leukemia

Selective pressure from TKI therapy can permit emergence of BCR::ABL1 kinase-domain mutations. Mutation testing is intended to support clinical decision-making when response is unsatisfactory, not as routine baseline testing in chronic-phase disease. NatureNatureEuropean LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia | Leukemia

When response is inadequate, distinguish pharmacologic or behavioral causes from resistant disease: verify medication access and adherence, review interacting drugs, establish whether the molecular rise is confirmed, reassess disease phase, and obtain mutation testing when indicated. A response categorized as failure usually mandates treatment change, whereas warning status is less deterministic. Nature+1NatureEuropean LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia | LeukemiaPubMedChronic Myelogenous Leukemia, Version 1.2014

Accelerated- and blast-phase CML require urgent specialist-directed management. The supplied sources confirm that CML occurs in chronic, accelerated, and blast phases and that preventing progression is the central goal of chronic-phase treatment, but do not provide sufficiently detailed evidence for a phase-specific regimen or transplant algorithm. PubMedPubMedChronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology - PubMed

Deep molecular responses achieved during TKI therapy have made treatment-free remission feasible for selected patients. Both NCCN and ELN-oriented sources emphasize that discontinuation requires careful monitoring rather than routine cessation after a favorable response. Nature+1Nature2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia | LeukemiaPubMedChronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology - PubMed

The available sources do not provide sufficient detail to specify a U.S. eligibility duration, exact deep-response threshold, post-discontinuation testing schedule, or molecular trigger for restarting therapy. In practice, use current guideline criteria and ensure reliable access to rapid, standardized BCR::ABL1 testing before discussing a discontinuation attempt. Nature+1Nature2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia | LeukemiaPubMedChronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology - PubMed